Tumor Lysis Syndrome as a Consequence of Chronic Lymphocytic Leukemia Treatment With Fludarabine and Rituximab

Abstract

A seventy-nine year old Caucasian male with a diagnosis of chronic lymphocytic leukemia presented with acute tumor lysis syndrome after treatment with two courses of fludarabine and one course of rituxan. In this article we report this rare complication, which has been reported only few times in the literature, and discuss the ways to prevent it from happening. J Med Cases. 2011;2(5):188-189 doi: https://doi.org/10.4021/jmc239w

Related Papers

• → Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Patients Treated with Fludarabine(1993)101 cited
• → 5.27 Low-Dose Fludarabine and Cyclophosphamide Combined With Rituximab Is a Safe and Effective Treatment Option for Elderly and Comorbid Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Preliminary Results of Project Q-lite, by the Czech CLL Study Group(2011)7 cited
• → Advancing Therapy For Chronic Lymphocytic Leukemia–the Role Of Rituximab(2004)12 cited
• Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.(1993)
• [Research advance on fludarabine resistance mechanisms in chronic lymphocytic leukemia cells].(2010)